• Full-year 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion), in line with upgraded guidance
• Q4 2025 unaudited Group revenue of approximately US$208 million, up 46% year-over-year
• Precision Medicine business revenue of approximately US$161 million, up 4% quarter-over-quarter

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) provided an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Key highlights include: Full-year (FY) 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion), in line with upgraded guidance of US$800-$820 million (previously US$770-800 million); Q4 2025 unaudited Group revenue of approximately US$208 million, up 46% year-over-year; Precision Medicine business revenue of approximately US$161 million, up 4% quarter-over-quarter, driven by the successful United States (U.S.) launch of Gozellix following reimbursement by Centers for Medicare and Medicaid Services (CMS); First international patients treated in Part 2 of the ProstACT Global Phase 3 study of TLX591-Tx in advanced prostate cancer; First U.S. patients treated in the SOLACE Phase 1 study of TLX090-Tx in patients with pain from bone metastases; and a strategic collaboration with Varian, a Siemens Healthineers company, to explore the combination of Telix's radiopharmaceuticals with external beam radiation therapy.

Telix reported full-year 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion), in line with upgraded guidance of US$800-$820 million (previously US$770-800 million).